JP2019517597A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517597A5 JP2019517597A5 JP2019517202A JP2019517202A JP2019517597A5 JP 2019517597 A5 JP2019517597 A5 JP 2019517597A5 JP 2019517202 A JP2019517202 A JP 2019517202A JP 2019517202 A JP2019517202 A JP 2019517202A JP 2019517597 A5 JP2019517597 A5 JP 2019517597A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- kit
- administered
- haf
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 33
- 208000004852 Lung Injury Diseases 0.000 claims description 12
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 12
- 231100000515 lung injury Toxicity 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 11
- 206010014561 Emphysema Diseases 0.000 claims description 10
- 239000000443 aerosol Substances 0.000 claims description 9
- 231100000331 toxic Toxicity 0.000 claims description 9
- 230000002588 toxic effect Effects 0.000 claims description 9
- 208000019693 Lung disease Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000006199 nebulizer Substances 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 5
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 5
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 5
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 201000009267 bronchiectasis Diseases 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 239000002575 chemical warfare agent Substances 0.000 claims description 5
- 208000007451 chronic bronchitis Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 150000002739 metals Chemical class 0.000 claims description 5
- 230000000414 obstructive effect Effects 0.000 claims description 5
- 239000000779 smoke Substances 0.000 claims description 5
- 239000008223 sterile water Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 206010003497 Asphyxia Diseases 0.000 claims description 4
- 241000283086 Equidae Species 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000000021 stimulant Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 231100000660 acute inhalation injury Toxicity 0.000 claims description 2
- 210000004381 amniotic fluid Anatomy 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000037080 exercise endurance Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 description 22
- 206010069351 acute lung injury Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021137896A JP7371948B2 (ja) | 2016-06-13 | 2021-08-26 | 肺障害の処置のための羊水液剤 |
| JP2023112316A JP2023121866A (ja) | 2016-06-13 | 2023-07-07 | 肺障害の処置のための羊水液剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349352P | 2016-06-13 | 2016-06-13 | |
| US62/349,352 | 2016-06-13 | ||
| US15/290,271 | 2016-10-11 | ||
| US15/290,271 US20170354692A1 (en) | 2016-06-13 | 2016-10-11 | Amniotic fluid formulation for treatment of lung disorders |
| PCT/US2017/037251 WO2017218535A1 (en) | 2016-06-13 | 2017-06-13 | Amniotic fluid formulation for treatment of lung disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021137896A Division JP7371948B2 (ja) | 2016-06-13 | 2021-08-26 | 肺障害の処置のための羊水液剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517597A JP2019517597A (ja) | 2019-06-24 |
| JP2019517597A5 true JP2019517597A5 (enExample) | 2020-07-27 |
| JP7126268B2 JP7126268B2 (ja) | 2022-08-26 |
Family
ID=60572075
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517202A Active JP7126268B2 (ja) | 2016-06-13 | 2017-06-13 | 肺障害の処置のための羊水液剤 |
| JP2021137896A Active JP7371948B2 (ja) | 2016-06-13 | 2021-08-26 | 肺障害の処置のための羊水液剤 |
| JP2023112316A Pending JP2023121866A (ja) | 2016-06-13 | 2023-07-07 | 肺障害の処置のための羊水液剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021137896A Active JP7371948B2 (ja) | 2016-06-13 | 2021-08-26 | 肺障害の処置のための羊水液剤 |
| JP2023112316A Pending JP2023121866A (ja) | 2016-06-13 | 2023-07-07 | 肺障害の処置のための羊水液剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20170354692A1 (enExample) |
| EP (1) | EP3468571B1 (enExample) |
| JP (3) | JP7126268B2 (enExample) |
| AU (1) | AU2017283482B2 (enExample) |
| CA (1) | CA3027489C (enExample) |
| ES (1) | ES2912075T3 (enExample) |
| WO (1) | WO2017218535A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038686A2 (en) | 2005-09-27 | 2007-04-05 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
| US9526770B2 (en) | 2011-04-28 | 2016-12-27 | Tissuetech, Inc. | Methods of modulating bone remodeling |
| JP2015528001A (ja) | 2012-07-11 | 2015-09-24 | ティッシュテック，インク． | Ｈｃ−ｈａ／ｐｔｘ３複合体を含む組成物およびその使用方法 |
| WO2016111899A1 (en) * | 2015-01-05 | 2016-07-14 | Petrucci Gary M | Methods and materials for treating lung disorders |
| WO2016138025A2 (en) | 2015-02-23 | 2016-09-01 | Tissuetech, Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
| EP3297645A4 (en) | 2015-05-20 | 2018-12-12 | Tissuetech, Inc. | Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells |
| TW201733600A (zh) | 2016-01-29 | 2017-10-01 | 帝聖工業公司 | 胎兒扶持組織物及使用方法 |
| US20180096104A1 (en) * | 2016-10-05 | 2018-04-05 | MED Inc. | Disease management system |
| CN108434441A (zh) * | 2018-04-17 | 2018-08-24 | 哈尔滨博翱生物医药技术开发有限公司 | 新型成纤维细胞生长因子-21类似物在治疗弥漫性间质性肺脏疾病中的应用 |
| CN110812369A (zh) * | 2018-08-10 | 2020-02-21 | 浙江楚沅生物科技有限公司 | 用于治疗组织坏死或改善心脏功能的药物 |
| EP3858372A1 (en) * | 2020-01-31 | 2021-08-04 | AdVita Lifescience GmbH | Human anti-inflammatory peptides for the inhalatory treatment of inflammatory pulmonary diseases |
| EP4096700A1 (en) * | 2020-01-31 | 2022-12-07 | AdVita Lifescience GmbH | Human anti-inflammatory peptides for the inhalatory treatment of inflammatory pulmonary diseases |
| CN113384300B (zh) * | 2020-03-11 | 2022-05-20 | 肖娓珠 | 一种妇产科羊水取样保存装置 |
| WO2021202947A1 (en) * | 2020-04-03 | 2021-10-07 | University Of Utah Research Foundation | Method for treating lung disease with cell-free amniotic fluid |
| US12377121B2 (en) * | 2020-04-10 | 2025-08-05 | Zeo Scientifix, Inc. | Compositions comprising nanoparticles, method of making and uses thereof |
| JP2023553048A (ja) * | 2020-12-02 | 2023-12-20 | ブリーズ リストア インコーポレイテッド | 呼吸器疾患を治療するための組成物、デバイス、及び方法 |
| AU2022264378A1 (en) * | 2021-04-27 | 2023-10-12 | AVITA Medical Americas, LLC | Regenerative bioactive suspension derived from freshly disaggregated tissue and methods of use in clinical therapies |
| US12281298B2 (en) | 2022-12-27 | 2025-04-22 | AVITA Medical Americas, LLC | System for automated preparation of a regenerative epidermal suspension and related methods of use |
| US11944742B1 (en) * | 2023-06-08 | 2024-04-02 | Microneb Tech Holdings, Inc. | Apparatus, methods, and systems for administering a medication to an animal |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1699479A (en) | 1928-04-27 | 1929-01-15 | Lilly Co Eli | Amniotic fluid and process of preparing it |
| US3752158A (en) | 1970-11-23 | 1973-08-14 | Snyder Manuf Co Inc | Apparatus and method for suprapubic drainage of the urinary bladder |
| US4308875A (en) | 1981-03-11 | 1982-01-05 | Universal Medical Instrument Corporation | Amniocentesis needle |
| US5436135A (en) | 1985-09-02 | 1995-07-25 | Pasteur Merieux Serums Et Vaccins | New preparation of placenta collagen, their extraction method and their applications |
| US5219576A (en) | 1988-06-30 | 1993-06-15 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US4977897A (en) | 1988-08-17 | 1990-12-18 | Robert Hurwitz | Amniocentesis needle with improved sonographic visibility |
| US5000192A (en) | 1990-01-02 | 1991-03-19 | Sealfon Andrew I | Prenatal specimen collection method |
| JP3647465B2 (ja) | 1995-06-07 | 2005-05-11 | オーガノジェネシス インコーポレイテッド | 再構成コラーゲン線維セグメント組成物およびその製法 |
| JP2731833B2 (ja) | 1995-06-26 | 1998-03-25 | 大同ほくさん株式会社 | 海洋生物を原料とした代用皮膚 |
| US7044945B2 (en) | 2001-03-30 | 2006-05-16 | Sand Bruce J | Prevention of regression in thermal ciliary muscle tendinoplasty |
| EP1549328A4 (en) | 2002-09-18 | 2009-07-08 | Emiliano Ghinelli | USE OF A HUMAN SHEEP SKIN COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF DISEASES AND STATES OF EYE AND SKIN |
| US20050079147A1 (en) | 2003-10-14 | 2005-04-14 | Bernard Delaey | Wound healing compositions and uses |
| EP1858533A4 (en) | 2005-02-22 | 2009-09-09 | Univ Johns Hopkins Med | USE OF THE AMNIOTIC FLUID FOR THE TREATMENT OF DISORDERS AND OCULAR LESIONS |
| EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
| US7928280B2 (en) | 2005-07-13 | 2011-04-19 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
| US20080064098A1 (en) | 2006-06-05 | 2008-03-13 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of maternal placental cells |
| US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
| AU2007318210B2 (en) | 2006-10-06 | 2014-02-20 | Celularity Inc. | Native (telopeptide) placental collagen compositions |
| US20090054350A1 (en) | 2007-08-23 | 2009-02-26 | Jean-Louis Tayot | Process for the sterile concentration of collagen preparations, and collagen preparations obtained |
| EP2197270B8 (en) | 2007-09-07 | 2020-03-04 | Surgical Biologics, LLC | Placental tissue grafts and improved methods of preparing and using the same |
| US9095569B2 (en) | 2008-04-18 | 2015-08-04 | Collplant Ltd. | Methods of generating and using procollagen |
| ES2532428T3 (es) | 2009-06-16 | 2015-03-26 | Baxter International Inc | Esponja hemostática |
| US20120010727A1 (en) | 2010-07-06 | 2012-01-12 | AFcell Medical | Amnion and chorion constructs and uses thereof in sport injury surgeries |
| WO2014072468A1 (en) * | 2012-11-09 | 2014-05-15 | Velin-Pharma A/S | Compositions for pulmonary delivery |
| US10485521B2 (en) * | 2013-05-10 | 2019-11-26 | MAM Holdings of West Florida, L.L.C. | Method for obtaining sterile human amniotic fluid and uses thereof |
| US20140336600A1 (en) | 2013-05-10 | 2014-11-13 | Carl Randall Harrell | Method for Obtaining Sterile Human Amniotic Fluid and Uses Thereof |
| WO2015134936A1 (en) | 2014-03-06 | 2015-09-11 | Amnio Technology Llc | Amnion derived therapeutic compositions and methods of use |
| WO2015134946A1 (en) * | 2014-03-06 | 2015-09-11 | Amnio Technology Llc | Amnion derived therapeutic compositions and methods of use |
| US9132156B1 (en) * | 2014-06-15 | 2015-09-15 | Amnio Technology Llc | Acellular amnion derived therapeutic compositions |
| KR20160001267A (ko) | 2014-06-27 | 2016-01-06 | 삼성전자주식회사 | 커넥터 플러그 및 커넥터 소켓 |
| US10517903B2 (en) | 2015-09-14 | 2019-12-31 | Amnio Technology Llc | Amnion derived therapeutic composition and process of making same |
| US9579350B1 (en) | 2016-02-25 | 2017-02-28 | MAM Holdings of West Florida, L.L.C. | Human amniotic fluid preparation having long-term stability |
| EP3432896A4 (en) * | 2016-03-23 | 2020-01-15 | MiMedx Group, Inc. | COMPOSITIONS AND METHODS OF TREATMENT USING AMNIOTIC LIQUID |
-
2016
- 2016-10-11 US US15/290,271 patent/US20170354692A1/en not_active Abandoned
-
2017
- 2017-06-13 JP JP2019517202A patent/JP7126268B2/ja active Active
- 2017-06-13 ES ES17737937T patent/ES2912075T3/es active Active
- 2017-06-13 CA CA3027489A patent/CA3027489C/en active Active
- 2017-06-13 EP EP17737937.7A patent/EP3468571B1/en active Active
- 2017-06-13 AU AU2017283482A patent/AU2017283482B2/en active Active
- 2017-06-13 WO PCT/US2017/037251 patent/WO2017218535A1/en not_active Ceased
-
2018
- 2018-01-22 US US15/876,988 patent/US11491189B2/en active Active
-
2021
- 2021-08-26 JP JP2021137896A patent/JP7371948B2/ja active Active
-
2022
- 2022-09-19 US US17/933,374 patent/US20230021477A1/en active Pending
-
2023
- 2023-07-07 JP JP2023112316A patent/JP2023121866A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517597A5 (enExample) | ||
| Lavorini et al. | Dilemmas, confusion, and misconceptions related to small airways directed therapy | |
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| CA2474479A1 (en) | Composition for inhalation | |
| JP2011520911A5 (enExample) | ||
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| US12171788B2 (en) | Methods and materials for treating lung disorders | |
| RU2006132038A (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| CN101244063A (zh) | 包含高效长效β2－激动剂和其它活性成分的药物组合物 | |
| JP2007520508A5 (enExample) | ||
| Rendell et al. | Assessment of N-acetylcysteine as a therapy for phosgene-induced acute lung injury | |
| RU2006132036A (ru) | Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей | |
| Popov et al. | In vitro and in vivo evaluation of the efficacy and safety of powder hydroxypropylmethylcellulose as nasal mucosal barrier | |
| JP2008533072A5 (enExample) | ||
| JP5501451B2 (ja) | 咳の治療のためのテオブロミン | |
| RU2010120806A (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид | |
| JP2011500731A5 (enExample) | ||
| EP3393517B1 (en) | Acetylsalicylic acid for use in the treatment of moderate to severe influenza | |
| JP2020019721A (ja) | 閉塞性気道疾患の抑制又は軽減のための組成物 | |
| EP2826479B1 (en) | Ameliorating agent for chronic obstructive pulmonary disease | |
| Herxheimer | The protective action of antihistaminic and sympathomimetic aerosols in anaphylactic microshock of the guinea-pig | |
| CH717180B1 (de) | Vasoaktives intestinales Peptid (VIP) zur Verwendung bei der Behandlung von medikamenteninduzierter Pneumonitis. | |
| Castro et al. | Asthma intervention research 2 (AIR2) trial | |
| TW202310855A (zh) | 使用一氧化二氮或任何吸入性麻醉劑治療covid-19及其他病毒感染、細菌感染、損傷、急性呼吸窘迫症候群或導致p物質水平急性升高引起細胞激素系統之病理性活化之病症 | |
| US20220054509A1 (en) | Methods of treatment for disease from coronavirus exposure |